NCT05772546 - Avatrombopag vs. Placebo for CIT in GI Malignancies | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

July 31, 2026

Conditions

Gastrointestinal CancerGastrointestinal NeoplasmsChemotherapy-Induced Thrombocytopenia

Interventions

DRUG

Avatrombopag

Thrombopoietin receptor agonist, tablet taken orally.

DRUG

Matching Placebo

Lactose monohydrate, tablet taken orally.

Trial Locations (4)

RECRUITING

University of Miami Sylvester Comprehensive Cancer Center, Miami

RECRUITING

Oregon Health and Science University Hospital, Portland

NOT_YET_RECRUITING

University of Washington Fred Hutchinson Cancer Center, Seattle

RECRUITING

Massachusetts General Hospital Cancer Center, Boston